Skip to content
RNAWiki

1,2-DIAMINOCYCLOHEXANE, TRANS-(-)-

  • Prescription medicine
  • Given by a clinician
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What 1,2-DIAMINOCYCLOHEXANE, TRANS-(-)- does in the body

Oxaliplatin injection, in combination with infusional fluorouracil and leucovorin, is indicated for: • adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. • treatment of advanced colorectal cancer.

From the FDA-approved label: Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific. In vivo studies have shown antitumor activity of oxaliplatin against colon carcinoma.

Why people take it. Oxaliplatin injection, in combination with infusional fluorouracil and leucovorin, is indicated for: • adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. • treatment of advanced colorectal cancer.

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

What the registries record it as

  • The substance registry classes this as chemical.

    FDA substance registry · 04ZR38536J · read 2026-08-29

  • Its recorded molecular formula is C8H14N2O4Pt, weighing 397.3.

    US prescribing information · 21a2bb1d-d91d-4f99-97dd-cc67fe99a090 · read 2026-08-30

Where each sentence above came from

The use the label states, quoted from it. No plain-language version of this sentence has been written.

The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.

No statement of the main limit is recorded.

The four opening statements run to 173 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Biomarker

A biomarker is a number from a test that stands in for something about health.

A picture of it, and where the picture fails

A biomarker is like a fuel gauge.

Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.

What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.

A measurable indicator used as a substitute for a clinical outcome of interest.

Placebo

A placebo is a dummy treatment given so the real one can be compared with it.

A picture of it, and where the picture fails

A placebo is like a blank control in an experiment.

Where that stops being true. A blank does nothing. People given a placebo often do get better.

What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.

An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.

Comparator

A comparator is whatever the treatment was measured against.

A picture of it, and where the picture fails

It is like the other runner in a race.

Where that stops being true. A race has one winner. A study can show both arms improved.

What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.

The control condition against which the experimental intervention is assessed.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

To determine the objective response rate of patients with metastatic colorectal cancer received the combination of drugs

The study did not show it

Who was studied
NCT01196260
How many people
8000
Study design
Phase 2/Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Intravenous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

3-year disease-free survival

The study did not show it

Who was studied
NCT00749450
How many people
6088
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Intravenous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Disease free Survival (DFS)

The study did not show it

Who was studied
NCT04089631
How many people
4812
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Intravenous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

disease free survival (DFS)

The study did not show it

Who was studied
NCT00646607
How many people
3756
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Intravenous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Disease-free Survival in Stage III Cancer Patients - Time to Event

The study did not show it

Who was studied
NCT00112918
How many people
3451
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Intravenous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Disease-free Survival (Arms A and D: Wild-type KRAS Patients)

The study did not show it

Who was studied
NCT00079274
How many people
3397
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Intravenous

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

  • & USAGE Oxaliplatin for injection USP, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: - adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. - treatment of advanced colorectal cancer.

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “The safety and effectiveness of oxaliplatin in pediatrics have not been established.”

    US prescribing information · 21a2bb1d-d91d-4f99-97dd-cc67fe99a090 · read 2026-08-30

  • On older people, the label states: “In the adjuvant treatment trial [see Clinical Studies ( 14.1 )] , 400 patients who received oxaliplatin with fluorouracil/leucovorin were greater than or equal to 65 years.”

    US prescribing information · 21a2bb1d-d91d-4f99-97dd-cc67fe99a090 · read 2026-08-30

  • On people who are pregnant, the label states: “Risk Summary Based on its direct interaction with DNA, oxaliplatin can cause fetal harm when administered to a pregnant woman.”

    US prescribing information · 21a2bb1d-d91d-4f99-97dd-cc67fe99a090 · read 2026-08-30

  • On people who are breastfeeding, the label states: “Risk Summary There are no data on the presence of oxaliplatin or its metabolites in human or animal milk or its effects on the breastfed infant or on milk production.”

    US prescribing information · 21a2bb1d-d91d-4f99-97dd-cc67fe99a090 · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Given by a clinician

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Intravenous

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form and route recorded on this substance.

No source is stored against this line.

Who oversees it

Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Suppression classes recorded: S3, S4, S6, S7.

No source is stored against this line.

What is in the pack

Sold as injectable, injection, solution, concentrate, injection, solution, injection, powder, lyophilized, for solution, given by the intravenous, injection route.

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

Recorded notes on how this is sold and what that means for what is in the pack.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Intravenous

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form used in the studies cited on this page.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 51 products list this as an active ingredient in the United States drug directory. 51 of them contain it and nothing else.

    FDA National Drug Code directory · 72266-162 · read 2026-08-29

  • They are sold as injection, powder, lyophilized, for solution, injection, solution, injection, solution, concentrate and powder, taken intravenous.

    FDA National Drug Code directory · 72266-162 · read 2026-08-29

  • The regulator's established pharmacologic class for it is platinum-based drug [epc] and platinum-containing compounds [ext].

    FDA National Drug Code directory · 72266-162 · read 2026-08-29

  • 24 published labels name it as an active ingredient. 24 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · 21a2bb1d-d91d-4f99-97dd-cc67fe99a090 · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · 21a2bb1d-d91d-4f99-97dd-cc67fe99a090 · read 2026-08-29

  • Oxaliplatin is intravenous at 3 DOSAGE FORMS AND STRENGTHS Injection: 50 mg (5 mg/mL) or 100 mg (5 mg/mL) clear, colorless solution in a single-dose vial., recorded as fda label in effect 2023-07-20 in the United States.

    US prescribing information · 21a2bb1d-d91d-4f99-97dd-cc67fe99a090 · read 2026-08-30

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.

Questions worth asking

  • Which of the trials of 1,2-DIAMINOCYCLOHEXANE, TRANS-(-)- studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of 1,2-DIAMINOCYCLOHEXANE, TRANS-(-)- are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

How many documents were read

  • 24 documents were read for this substance.

    RNAWiki source record

  • 24 of them state the same proteinBinding, and they agree.

    RNAWiki source record

  • 24 of them state the same volumeOfDistribution, and they agree.

    RNAWiki source record

Where else this substance is registered

FDA substance identifier (UNII)
04ZR38536J
RxNorm concept
1736776

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Quoted from a stored source.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Passed

    Safety mode resolved

    Suppression classes recorded: S3, S4, S6, S7.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

  • 33 approved applications cover products containing this substance. The earliest was NDA021492, approved 20020809 to SANOFI AVENTIS US.

    Drugs@FDA application register · NDA021492 · read 2026-08-29

  • Marketing status on the register: discontinued, none (tentative approval) and prescription.

    Drugs@FDA application register · NDA021492 · read 2026-08-29

  • The earliest marketing start date recorded for a listed product is 20031111.

    FDA National Drug Code directory · 72266-162 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

9 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • What was measured, goal by goal — found nothing in the sources checked.
  • How close this is to real life — found nothing in the sources checked.
  • The path through the body — found nothing in the sources checked.
  • Felt, measured, or meaningful — found nothing in the sources checked.
  • How long anything takes — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (7)

On the 1,2-DIAMINOCYCLOHEXANE, TRANS-(-)- label: indicated for what?

"Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for: • adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. • treatment of advanced colorectal cancer.": indications and usage on 1,2-DIAMINOCYCLOHEXANE, TRANS-(-)-'s label. DailyMed label · e51a62ba-d163-4c57-835c-8c86cf097e40 · 2026-08-07

1422 registered trials of 1,2-DIAMINOCYCLOHEXANE, TRANS-(-)- — at which phases?

Registered studies posting no result
1109 of 1422

1422 registered studies of 1,2-DIAMINOCYCLOHEXANE, TRANS-(-)-: 935 phase2, 314 phase1, 284 phase3, 30 na, 18 na or unstated, 12 phase4, 7 early phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01

2741 with a PubMed record

Show the evidence
  • phase2
    935
  • phase1
    314
  • phase3
    284
  • na
    30
  • na or unstated
    18
  • phase4
    12
11 more recorded rows
  • early phase1
    7
  • completed
    589
  • unknown
    247
  • recruiting
    191
  • terminated
    161
  • active not recruiting
    105
  • not yet recruiting
    80
  • withdrawn
    41
  • suspended
    4
  • approved for marketing
    2
  • enrolling by invitation
    2

recorded 2026-09-01 · last checked 2026-09-04

183 of 1,2-DIAMINOCYCLOHEXANE, TRANS-(-)-'s trials stopped: safety, futility/efficacy, accrual/recruitment, funding/business, sponsor decision unspecified, other?

safety (9), futility/efficacy (9), accrual/recruitment (71), funding/business (20), sponsor decision unspecified (12) and other (62): 1,2-DIAMINOCYCLOHEXANE, TRANS-(-)-'s stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01

"Administratively complete."; 183 of 1422 registered studies

Show the evidence

Trial

  • NCT00005856
    terminated; "Administratively complete."
  • NCT00006015
    terminated; "lack of sufficient accrual"
  • NCT00006121
    terminated; "low accrual"
  • NCT00043004
    terminated; "low accrual"
  • NCT00066625
    terminated; "Administratively complete."
  • NCT00070122
    terminated; "Administratively complete."
14 further recorded trials
  • NCT00070265
    terminated; "Administratively complete."
  • NCT00070434
    withdrawn; "poor accrual"
  • NCT00077233
    terminated; "Poor accrual"
  • NCT00087334
    terminated; "Withdrawn due to poor/low accrual"
  • NCT00101075
    terminated; "Slow Accrual"
  • NCT00118105
    withdrawn; "Budget Constraints"
  • NCT00129870
    terminated; "Unplanned interim analysis by DSMB indicated possible reduced response rate with the addition of Ca/Mg in pooled population. Further analysis pending."
  • NCT00145418
    terminated; "low enrollment"
  • NCT00184028
    terminated; "Insufficient Accrual"
  • NCT00216073
    terminated; "Lack of patient accrual"
  • NCT00226941
    terminated; "The response rate observed in the phase 1 portion of the study did not merit further evaluation in phase 2 portion of the study."
  • NCT00227617
    terminated; "Low accrual"
  • NCT00244348
    withdrawn; "Investigator has left institution"
  • NCT00256269
    terminated; "Study was terminated by funding entity"

recorded 2026-09-01 · last checked 2026-09-04

Human studies of 1,2-DIAMINOCYCLOHEXANE, TRANS-(-)- used Oxaliplatin 130 mg/m^2 — over how long?

studies of 1,2-DIAMINOCYCLOHEXANE, TRANS-(-)- used the recorded amount. ClinicalTrials.gov · 2026-09-01

17 recorded entries; human; IV, injection; also "Oxaliplatin 130 mg/m^2", "Oxaliplatin 85 mg/m^2", "Oxaliplatin 85 mg/m2 IV q 2 weekly Until disease progression, unacceptable toxicity,"

Show the evidence

human

  • NCT00069095
    Oxaliplatin 130 mg/m^2
  • NCT00069095
    Oxaliplatin 85 mg/m^2
  • NCT00177307
    IV; Oxaliplatin 85 mg/m2 IV q 2 weekly Until disease progression, unacceptable toxicity,
  • NCT00447122
    Oxaliplatin 100mg/m2
  • NCT01980407
    L-OHP (50mg)
  • NCT02076594
    Eloxatin 5 mg/mL
11 more recorded rows
  • human NCT02280070
    L-OHP (130mg/m2)
  • human NCT02280070
    L-OHP (85 mg/m2)
  • human NCT02842580
    ELOXATINE 5 mg/ml
  • human NCT03422523
    Oxaliplatin 100 MG
  • human NCT04246684
    Oxaliplatin, 85 mg/m2
  • human NCT04246684
    Oxaliplatin 50 mg/m2
  • human NCT04246684
    Oxaliplatin 85 mg/m2
  • human NCT04246684
    Oxaliplatin, 130 mg/m2
  • human NCT05980481
    Oxaliplatin（130mg/m2 ）
  • human NCT05980481
    Oxaliplatin（100mg/m2 ）
  • human NCT05980481
    injection; Oxaliplatin injection（100mg/m2 ）

recorded 2026-09-01 · last checked 2026-09-04

Which running trial of 1,2-DIAMINOCYCLOHEXANE, TRANS-(-)- could settle lifespan?

NCT04821284 measures Progression-free survival, reading out 2026-02-28.

113 open trials; n 120; "Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer"

Show the evidence

Trial

  • NCT04821284
    "Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer"; n 120; "Progression-free survival"; 2026-02-28
  • NCT06282445
    "Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer"; n 36; "Progression-free survival"; 2026-03-31
  • NCT04094688
    "Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer"; n 455; "Progression-free Survival (PFS)"; 2026-07-01
  • NCT05568095
    "A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body"; n 1040; "Overall survival"; 2026-08
  • NCT03504397
    "A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer."; n 565; "Progression Free Survival (PFS)"; 2026-09-30
  • NCT03653507
    "A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)."; n 507; "Progression Free Survival (PFS)"; 2026-09-30
14 further recorded trials
  • NCT06094868
    "Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer"; n 45; "Progression-free survival (PFS)"; 2026-10
  • NCT05564403
    "Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)"; n 66; "Overall survival (OS)"; 2026-10-01
  • NCT02008656
    "Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management"; n 358; "disease-free survival (DFS)"; 2026-11
  • NCT04854668
    "A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer"; n 748; "Progression Free Survival (PFS) assessed by IRC"; 2026-12
  • NCT05476796
    "Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer"; n 118; "Progression free-survival"; 2026-12
  • NCT05699746
    "CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD"; n 38; "Recurrence-free survival"; 2026-12
  • NCT03764553
    "Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer"; n 320; "Progression free survival"; 2026-12-01
  • NCT06788171
    "PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM"; n 35; "Progression-free-Survival"; 2026-12-01
  • NCT02912559
    "Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair"; n 712; "Disease Free Survival (DFS)"; 2026-12-18
  • NCT05171660
    "Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer"; n 446; "Progression free survival time"; 2026-12-30
  • NCT01924819
    "Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma"; n 574; "Overall survival"; 2026-12-31
  • NCT06341595
    "Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM"; n 40; "Recurrence free survival (RFS)"; 2026-12-31
  • NCT05062317
    "ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases"; n 120; "To establish the 1-year recurrence-free survival rate following liver resection of CLM with curative intent among ctDNA-negative patients who receive risk-stratified postoperative chemotherapy"; 2027-02-28
  • NCT01081262
    "Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer"; n 50; "Overall Survival"; 2027-03-12

Which 286 trials of 1,2-DIAMINOCYCLOHEXANE, TRANS-(-)- posted no result?

Posted no result
286 of 286 completed trials
Registrations
NCT00006062, NCT00001835, NCT00003427, NCT00275210, NCT00006050 and NCT00004190, and 280 more
Completion dates
oldest 2001-05; newest 2024-08-27
Show the evidence

Trial

  • NCT00006062
    2001-05
  • NCT00001835
    2001-12
  • NCT00003427
    2002-04
  • NCT00275210
    2003-04
  • NCT00006050
    2003-04-04
  • NCT00004190
    2003-06
14 further recorded trials
  • NCT00005068
    2003-06
  • NCT00004126
    2003-08
  • NCT00004127
    2003-08
  • NCT00008060
    2003-12
  • NCT00004257
    2004-01
  • NCT00005035
    2004-03
  • NCT00040820
    2004-03
  • NCT00004187
    2004-04
  • NCT00005837
    2004-06
  • NCT00005839
    2004-06
  • NCT00005836
    2004-07
  • NCT00049101
    2004-08
  • NCT00003594
    2004-10
  • NCT00055822
    2004-10

At the median, 1,2-DIAMINOCYCLOHEXANE, TRANS-(-)-'s trials enrolled 60 people — anything larger?

Median enrolment
60
Largest enrolment
6088
Registered trials counted
1373
Where it is registered
Identifiers, relations and other names

The exact record

PubChem CID
9887054
CAS number
61825-94-3
RxCUI
1736776
InChIKey
SSJXIUAHEKJCMH-PHDIDXHHSA-N
Also called
Oxaliplatin
Trade name
Eloxatin
Also called
(SP-4-2-(1R-TRANS))-(1,2-CYCLOHEXANEDIAMINE-N,N')(ETHANEDIOATO(2-)-O,O')PLATINUM, Folfox component oxaliplatin, OXALIPLATIN [EP IMPURITY], OXALIPLATIN [EP MONOGRAPH], OXALIPLATIN [JAN], OXALIPLATIN [MART.]
Development code
JM-83, L-OHP, MBP-426 (LIPOSOMAL OXALIPLATIN), NSC-266046
Component
Oxaliplatin
Sources (5)

Sources

  • CLINICALTRIALS_SNAPSHOT K1:88RM10ID0P ·
  • ClinicalTrials.gov clinicaltrials.gov ·
  • drugsfda drugsfda ·
  • DailyMed label e51a62ba-d163-4c57-835c-8c86cf097e40 ·
  • Drugs@FDA K1:88RM10ID0P ·

ClinicalTrials.gov — US Government work · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 5 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.